TORCH
2007
Towards a Revolution in COPD Health
In 6,112 patients with moderate-to-severe COPD, salmeterol-fluticasone reduced 3-year all-cause mortality only borderline-significantly compared with placebo.
Result
Efficacy: All-cause mortality at 3 yearsHR 0.825 · P = 0.052
Below 1 favours salmeterol-fluticasone, above 1 favours placebo.
- Absolute difference
- 2.6 points
The absolute difference is derived from the event rates.
Also reported: Exacerbations reduced 25%. Pneumonia 19.6% vs 12.3%.
- Subtopic
- ICS/LABA
- Design
- Multicentre RCT
- Relevance
- Important: one of several pillars.
- Source
- Calverley PMA, et al. N Engl J Med. 2007;356(8):775-789.doi 10.1056/NEJMoa063070
Discussion & critique
First large mortality trial in COPD; established LABA/ICS for exacerbation reduction and surfaced the ICS-pneumonia signal that persists in later trials.